Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mycophenolate mofetil - Roche

Drug Profile

Mycophenolate mofetil - Roche

Alternative Names: CellCept; Cellcept Capsules; ME MPA; Munoloc; R99; RS-61443

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Aspreva Pharmaceuticals Corporation; Chugai Pharmaceutical; Roche; Roche Palo Alto
  • Class Acyclic acids; Fatty acids; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris; Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart transplant rejection; Liver transplant rejection; Lung transplant rejection; Lupus nephritis; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Discontinued Multiple sclerosis; Myasthenia gravis; Pemphigus vulgaris; Psoriasis

Most Recent Events

  • 14 May 2016 Launched for Lupus nephritis in Japan (PO, Capsule)
  • 14 May 2016 Launched for Lupus nephritis in Japan (PO, Powder)
  • 13 May 2016 Registered for Lupus nephritis in Japan (PO, Capsule)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top